Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Stallergenes Greer.

    Client Virtual Booth

    STALLERGENES GREER

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Stallergenes Greer
    unitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Tower bridge House, St Katharine’s Way, London, E1W 1DD
    Telephone
    Telephone
    +44 20 7239 4508
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.stallergenesgreer.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/stallergenesgreer
    Twitter
    Twitter
    https://twitter.com/StallergenesCom

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Stallergenes Greer Announces Global Agreement with Nestlé Regarding the Peanut Allergy Oral Immunotherapy Treatment Palforzia®

    Details:

    Through the divestment, Nestle sells its peanut-allergy treatment business to stallergenes greer, including Palforzia (peanut allergen powder-dnfp), an oral immunotherapy treatment approved for the mitigation of allergic reactions, including anaphylaxis.


    Lead Product(s): Peanut Allergen Powder-dnfp

    Therapeutic Area: Immunology Product Name: Palforzia

    Highest Development Status: ApprovedProduct Type: Large molecule

    Recipient: Nestle

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Divestment September 04, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Stallergenes Greer Initiates a European Paediatric Phase III Study With Staloral® Birch

    Details:

    Staloral Staloral Birch is a sublingual solution of allergen extracts for AIT. It is indicated in the treatment of seasonal or perennial allergic rhinitis, rhino-conjunctivitis and mild to moderate allergic asthma


    Lead Product(s): Birch Pollen Extract

    Therapeutic Area: Immunology Product Name: Staloral Birch

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 25, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Positive Results of EfficAPSI Real-World Study Confirm Significant Benefit of Sublingual Liquid AIT Treatment on the Onset and Worsening of Asthma in Pa...

    Details:

    Study results were consistent across all age groups showed a reduction of risk of asthma onset of more than 20% observed in patients undergoing treatment with sublingual liquid AIT and symptomatic drugs versus patients treated with symptomatic drugs only.


    Lead Product(s): Allergen Extract

    Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Staloral

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator:

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 02, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Stallergenes Greer Receives Market Approval in Austria for Its Sublingual Allergen Immunotherapy Tablet for Household Mite Allergy

    Details:

    The STAGR320 phase III clinical trial, which included 1,600 patients from 231 participating investigative sites in 13 countries, assessed the treatment of HDM-induced allergic rhinitis in adult and adolescent patients.


    Lead Product(s): House Dust Mite Allergen Extracts

    Therapeutic Area: Immunology Product Name: Actair

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 09, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search